Stifel on uniQure BV (QURE): 'AMT-130 3yr data in Huntington's Disease exceeded our expectations'
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Buy rating and $30.00 price target on uniQure BV (NASDAQ: QURE).The analyst comments "We're ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
